The pharmaceutical industry is trending towards a portfolio of modern modalities at higher potencies, with more very low dose therapies being processed than ever before. The SMi HPAPI conference serves as a forum for subject matter experts in the field to network and discuss key areas of this domain of the pharmaceutical industry. The conference will explore hazard identification and the determination of health-based exposure limits for both occupational health and product cross- contamination assessments, effective risk assessments, controls including engineering containment, administrative and PPE controls, occupational hygiene testing and much more. I look forward to welcoming attendees to this insightful conference in May.
Comments